Speakers

Peter received a Ph.D. in analytical chemistry from the University of Kansas in 1991. He has over 15 years in pharmaceutical development experience from both the NDA and ANDA side, as well as 15 years at the FDA supporting generic drug quality review across a wide range of therapeutic areas. He has been involved in important FDA initiatives like the PEPFAR program for prioritizing AIDS drugs for developing countries, as well as the current KASA initiative for structured drug product assessment.